Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- The relation between treatment benefit and underlying risk in meta-analysisBMJ, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Communicating the Benefits of Chronic Preventive TherapyMedical Decision Making, 1995
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 1994
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985